| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Service revenue | ||||||
- | - | - | - | 1,375,847 | 1,266,596 | |
Reimbursement revenue | ||||||
- | - | - | - | 238,036 | 192,990 | |
Revenue | ||||||
3,066,262 | 2,871,922 | 2,259,389 | 1,811,711 | 1,613,883 | 1,459,586 | |
Operating expenses: | ||||||
Selling, general and administrative expenses | ||||||
394,925 | 371,795 | 321,987 | 269,893 | 246,417 | 253,970 | |
Transaction-related costs | ||||||
1,835 | 35,817 | 87,709 | 44,834 | 0 | - | |
Depreciation and amortization expense | ||||||
114,898 | 112,247 | 78,227 | 69,506 | 77,952 | 96,564 | |
(Gain) loss on disposal of fixed assets, net | ||||||
-1,058 | -120 | -358 | -753 | -652 | -5 | |
Income from operations | ||||||
363,925 | 281,312 | 176,225 | 162,349 | 164,298 | 56,839 | |
Interest expense, net | ||||||
-51,987 | -57,399 | -46,729 | -54,913 | -61,747 | -81,939 | |
Loss on modification or extinguishment of debt | ||||||
-3,928 | -952 | -15,023 | -38,178 | 0 | -25,036 | |
Foreign currency gains, net | ||||||
-2,257 | -1,043 | -39,622 | 24,029 | 14,048 | 10,538 | |
Other expense, net | ||||||
174 | -371 | -304 | 607 | -1,434 | -2,254 | |
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest | ||||||
305,927 | 221,547 | 74,547 | 93,894 | 115,165 | -41,852 | |
Provision for income taxes | ||||||
62,808 | 67,232 | -12,623 | 28,494 | 30,004 | -8,154 | |
Income before equity in income of unconsolidated joint ventures | ||||||
243,119 | 154,315 | 87,170 | 65,400 | 85,161 | -33,698 | |
Income (Loss) from Equity Method Investments | ||||||
0 | 143 | 123 | 2,775 | -3,396 | -2,044 | |
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | ||||||
243,119 | 154,458 | 87,293 | 68,175 | 81,765 | -35,742 | |
Net income attributable to noncontrolling interest | ||||||
99 | 553 | 366 | 0 | 0 | - | |
Net income attributable to PRA Health Sciences, Inc. | ||||||
243,020 | 153,905 | 86,927 | 68,175 | 81,765 | - | |
Earnings Per Share [Abstract] | ||||||
Basic (in dollars per share) | ||||||
3.77 | 2.40 | 1.39 | 1.12 | 1.36 | -0.83 | |
Diluted (in dollars per share) | ||||||
3.68 | 2.32 | 1.32 | 1.06 | 1.29 | -0.83 | |
Weighted average common shares outstanding: | ||||||
Weighted Average Number of Shares Outstanding, Basic | ||||||
64,506 | 64,123 | 62,437 | 60,759 | 59,965 | 42,897 | |
Weighted Average Number of Shares Outstanding, Diluted | ||||||
66,004 | 66,341 | 65,773 | 64,452 | 63,207 | 42,897 | |
Direct Costs [Member] | ||||||
Cost of revenues | ||||||
1,539,541 | 1,500,226 | 1,283,868 | 1,032,688 | 886,528 | 859,218 | |
Reimbursable expenses | ||||||
Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization | ||||||
650,080 | 570,405 | 311,015 | 231,688 | 238,036 | 192,990 | |
Reimbursable investigator fees | ||||||
Cost of revenues | ||||||
- | - | - | 0 | - | - | |